Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT06706908
Active, not recruiting Observational

Innovative Spinopelvic Solutions With Real-World Evidence

NCT06706908 · tracked via the Priya Life Science USA tracker
Sponsor
SI-BONE, Inc
Phase
Observational
Started
2024-12-15
Last updated
2026-04-24

Condition(s) studied

Sacroiliac Joint DysfunctionSacroiliac Joint Pain

Investigational drug(s) / intervention(s)

Health questionnaires

Health questionnaires: Participants are expected to complete a series of health questionnaires (i.e. numerical rating scale, Oswestry Disability Index) relevant to their treatment using a SI-BONE implant.

Study summary

INSPIRE is a prospective decentralized study evaluating post-operative health outcomes in patients who undergo a procedure using implants manufactured by SI-BONE.

Eligibility

Sex
ALL
Min age
21 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age \> 21 at time of screening. 2. Patient will undergo a procedure utilizing an iFuse Implant family product. 3. Patient is comfortable communicating in written and spoken English. 4. Patient is willing and able to complete study questionnaires online, using either a smartphone, tablet, or computer. 5. Patient is willing and able to provide informed consent to participate Exclusion Criteria: 1. Patient has fibromyalgia. 2. Patient has a pain pump. 3. Patient is currently receiving or seeking worker's compensation, disability remuneration, and/or involved in injury litigation

Primary outcome measure(s)

  • Change in patient reported outcomes — From enrollment and at the following timepoints, 1-, 3-, 6-, and 12-months.
    Change in pain as rated on a numerical rating scale (NRS), 0 being no pain and 10 being the worst pain imaginable at baseline and follow-up timepoints.

Trial sites (1)

FacilityCityRegionStatus
SI-BONE Santa Clara California

More SI-BONE, Inc. trials in the USA

iFuse TORQ for the Treatment of Sacroiliac Joint Dysfunction Active, not recruiting
Pelvic Fixation and Fusion During Multilevel Spinal Surgery Active, not recruiting
Real World Evidence of SI-BONE's iFuse TORQ TNT Advancing Treatment of Pelvic Ring Fractures Recruiting

Other trials for the same condition

LINQ® Procedure vs. Conventional Medical Management for Sacroiliac Dysfunction Recruiting
iFuse TORQ for the Treatment of Sacroiliac Joint Dysfunction Active, not recruiting
Post-Market Clinical Study Using TRAQ™ for Minimally Invasive Posterior Sacroiliac Joint Fusion Recruiting
Post-Market Clinical Study on a Modular SI Joint Fusion System Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06706908 on ClinicalTrials.gov ↗ ← All trials in the USA